John Ivory

John Ivory is a seasoned pharmaceutical executive with over 25 years of industry experience, currently serving as Head of Commercialisation at tranScrip. His career spans leading global companies including AstraZeneca, Elan, Servier, Genzyme, and Sanofi, where he held a broad range of senior roles in Sales, Marketing, Brand Intelligence & Forecasting, Market Development, International Marketing, Sales and Marketing Operations, Business Unit Leadership, and General Management. With a proven track record of strategic leadership, he has overseen European and global markets, consistently delivering commercial growth, orchestrating successful new product launches, and spearheading business transformation efforts.

Throughout his career, John has demonstrated deep expertise in developing and implementing global brand strategies, while tailoring them for local execution. He has activated change within organisations by creating high-performing teams and fostering a culture of continuous improvement. His success spans multiple therapy areas—including rare diseases, oncology, respiratory, CNS and pain, cardiovascular, and infectious diseases—and he has extensive experience working with diverse product types such as small molecules, biologicals, devices, and diagnostics.

Among the notable therapies and brands he has worked on are Losec, Nexium, Symbicort, Prialt, Zonegran, Valdoxan, Protelos, Procoralan, Thyrogen, Mozobil, Thymoglobulin, Cerezyme, Cerdelga, Fabrazyme, Aldurazyme, Myozyme, Nexviadyme, Xenpozyme, Cablivi, Enjaymo, and Rilzabrutinib.

John’s dynamic background is supported by a BA (Hons) in Marketing, a Diploma in Market Research, and completion of the HEC Data Driven Transformation programme. He is known for forging trusting stakeholder relationships and navigating complex market access and policy environments. His leadership approach has led to the reorganisation of European teams into a “Global” structure, enabling faster, more efficient responses to local market needs and resulting in increased patient access to innovative therapies. A believer in results-driven and patient-focused strategies, he has been recognised for creating and executing new product launch excellence, including multiple breakthrough launches in rare diseases that significantly improved both revenue and patient outcomes.

His achievements include a successful record of P&L ownership and growth across multiple therapy areas and geographies. He has activated European-wide taskforces to remove policy and market access barriers, ensuring timely approval and reimbursement for novel treatments. John also remains committed to broader industry collaboration, having previously served as a member of the ABPI Rare Diseases Strategy Forum. Through every role, he brings a wealth of commercial acumen, cultural awareness, and a passionate drive for improving patient care, positioning him as a transformative leader in the life sciences sector.